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Abstract 
Background: Molecular and cellular pathophysiological events occurring in the majority of rare kidney diseases 
remain to be elucidated. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) is a rare 
autosomal recessive disorder caused by mutations in either CLDN16 or CLDN19 genes. This disease is characterized 
by massive urinary wasting of magnesium and calcium, osmosis deregulation and polyuria. Patients with p.G20D 
homozygous mutation in CLDN19 gene exhibit different progression to kidney failure suggesting that beyond the 
pathogenic mutation itself, other molecular events are favoring disease progression. Due to the fact that biopsy is not 
clinically indicated in these patients, urinary exosome‑like vesicles (uEVs) can be envisioned as a valuable non‑invasive 
source of information of events occurring in the kidney. Exosome research has increased notably to identify novel 
disease biomarkers but there is no consensus standardized protocols for uEVs isolation in patients with polyuria. For 
this reason, this work was aimed to evaluate and refine different uEVs isolation methods based on differential centrifu‑
gation, the gold standard method.
Results: Characterization by NTA, cryo‑TEM and immunoblotting techniques identified the most appropriate pro‑
tocol to obtain the highest yield and purest uEVs enriched fraction possible from urine control samples and FHHNC 
patients. Moreover, we tested five different RNA extraction methods and evaluated the miRNA expression pattern by 
qRT‑PCR.
Conclusions: In summary, we have standardized the conditions to proceed with the identification of differentially 
expressed miRNAs in uEVs of FHHNC patients, or other renal diseases characterized by polyuria.
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Background
Rare kidney diseases include at least 150 different inher-
ited disorders that can affect all the segments in the 
nephron impairing homoeostatic processes [1]. The high 
number of rare kidney diseases, their low prevalence and, 
in many cases, their highly phenotypic variability leads to 
a poor knowledge of the natural history and mechanisms 
underlying disease progression.
Familial hypomagnesemia with hypercalciuria and 
nephrocalcinosis (FHHNC) is a rare autosomal-reces-
sive disorder caused by mutations in either CLDN16 
or CLDN19 genes [2–4]. The loss-of-function of one of 
those genes leads to massive urinary wasting of mag-
nesium and calcium causing osmosis deregulation and 
polyuria. Although two-thirds of the affected patients 
in Spain are presenting a specific founder mutation 
(c.59G>A; p.G20D) in CLDN19 gene, there are important 
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renal disease (ESRD) [5–10]. This suggests the existence 
of other non-identified molecular events that contribute 
to the physiopathology of the disease, promoting ESRD 
progression. Because kidney biopsy samples, which could 
allow the study of those intra-renal processes, are not 
clinically indicated in most patients with FHHNC, blood 
and urine are the only available samples for the discovery 
of surrogated markers that might indicate disease pro-
gression in those patients.
Exosomes are small (30–150  nm) membrane vesicles 
of endocytic origin contained into multivesicular bod-
ies and released constitutively through fusion with the 
plasma membrane [11–13]. Exosomes can act as cell-to-
cell communication mediators that trigger intracellular 
signaling pathways [14–18] and have been pointed out 
as a promising source of biomarkers, since their cargo 
(protein, DNA, mRNA and non-coding RNA) represents 
their cellular origin content [18–21]. The biogenesis and 
excretion of nanovesicles take place in every segment 
of the renal nephron [12], thereby, analysis of urinary 
vesicles should provide information about the patho-
physiological state of the entire renal tubule and might 
be considered a reliable non-invasive source of cellular 
events information [12, 22]. It is important to remark that 
due to the absence of exosome specific markers that lead 
to an uncertain origin of the isolated vesicles (released 
from multivesicular bodies or other intracellular com-
partments), urinary exosome-like vesicles (uEVs) are 
considered as the enriched fraction of nanovesicles hav-
ing similar size and morphology.
Diverse studies have shown that nanovesicles can be 
recovered from urine by ultracentrifugation, ultrafiltra-
tion or by other techniques [12, 23, 24]; however, these 
studies focused predominantly on patients with normal 
urine output. There is no information about the efficiency 
of those methods in isolating nanovesicles from patients 
with urinary ionic deregulation and massive urine wast-
ing. In diseases coursing with severe polyuria, such as 
FHHNC, urinary exosome-enrichment may be lower 
than in a control sample. Therefore, we decided that dif-
ferential centrifugation, which allows an unlimited urine 
volume input, might be the best method to obtain suf-
ficient exosome yields for subsequent analysis. So far, 
diverse differential centrifugation protocols for urinary 
exosome isolation have been described in the literature, 
including: (a) DTT treatment step to release entrapped 
exosomes from the polymeric Tamm–Horsfall protein 
(THP) networks, the most abundant protein in urine 
[25–30]; (b) large extracellular vesicles removal through 
a 0.22 µm filter to restrict the co-precipitation of larger 
extracellular vesicles presents in urine [26]; (c) exosome-
enriched fraction precipitation speed ranging 100,000–
200,000×g [26, 28, 29, 31].
To the best of our knowledge, there is no consensus 
protocol to isolate uEVs of patients with polyuria. There-
fore, in the present study we propose an optimized dif-
ferential centrifugation method for uEVs isolation that 
would be useful for further identification of markers 
linked to disease outcome in patients with FHHNC [32].
One of the most appealing features of isolating urinary 
exosomes is explained by their miRNA cargo. In particu-
lar, exosomal miRNAs have become an object of study 
in many biomedical areas to identify novel and highly 
promising biomarkers for kidney diseases [20, 33, 34]. In 
this work, we also evaluated five different RNA extraction 
methods and selected the one that provided with the best 
yield and purity for further differential miRNAs expres-
sion analysis.
Methods
In order to standardize a protocol for uEVs isolation in 
patients with polyuria we evaluated and refined dif-
ferent uEVs isolation methods based on differential 
centrifugation.
Urinary exosome‑like vesicles isolation
We performed different approaches (based on differential 
centrifugation) named P1-P7 (Fig. 1).
Approximately 500  mL of urine from seven healthy 
human donors (control samples), 4 females and 3 males, 
were collected in sterile recipients, pooled and main-
tained at 4  °C for 24  h. These conditions recapitulate 
those suffered by FHHNC patient’s samples collected 
at different hospitals of Spain. Protease inhibitor cock-
tail (PIC) (#S8820 Sigma-Aldrich, Darmstadt, DE) was 
added to the sample at 1 µL/mL and centrifuged 10 min 
at 2500×g to remove cell debris. Samples were centri-
fuged 15  min at 17,000×g to pull down cell fragments, 
apoptotic cells and larger vesicles. The supernatant (SN0) 
was kept on ice while the pellet obtained (P0) was treated 
with DTT (#A2948 AppliChem, Barcelona, ES) (200 mg/
mL) at 95 °C for 2 min or at 37 °C for 10 min and vortexed 
every 2 min. Both DTT treated pellets were centrifuged 
at 17,000×g for 20  min and supernatants (SNa-SNb) 
were ultracentrifuged (Sorvall WX90; AH629 rotor) at 
100,000×g for 2 h, obtaining P2 and P3 respectively.
SN0 was divided into five 100  mL aliquots that were 
processed by different procedures: (a) SN0 ultracentrifu-
gation at 100,000×g for 2 h (P1); (b) combination of SN0 
with SNb and ultracentrifugation at 100,000×g for 2  h 
(P4); (c) SN0 filtration through a 0.22 µm-pore followed 
by ultracentrifugation at 100,000×g for 2 h (P5); (d) SN0 
double ultracentrifugation for 2 h at 100,000×g (P6) and; 
(e) SN0 ultracentrifugation at 200,000×g for 1  h (P7), 
all them performed at 4  °C. All the uEVs isolated were 
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resuspended in 150  µL of cold and pre-filtered PBS 1× 
and saved at − 80 °C.
Urine samples from 20 FHHNC patients (8 women 
and 12 men) were collected at hospitals from different 
geographical places in Spain and individually processed 
at Hospital Universitari Vall d’Hebron, as previously 
described. Clinical and genetic data from these patients 
is included in the RENALTUBE Spanish Registry (www.
renal tube.com) [32].
Urinary exosome‑like vesicles characterization
uEVs obtained following the procedure described above 
were characterized by three methods: Nanoparti-
cle Tracking Analysis (NTA), Cryogenic Transmission 
Electron Microscopy (cryo-TEM) and immunoblotting 
techniques.
NTA
NTA was performed using NanoSight NS300 (Malvern 
Instruments). Videos were recorded and analyzed using 
NTA software v3.1 (NanoSight Ltd., UK). Background 
extraction was applied and the automatic setting for min-
imum track length, blur settings and minimum expected 
particle size were established. uEVs samples were diluted 
to optimal concentrations according to the manufactur-
er’s protocol. Each measure was carried out in triplicate 
of 60  s recordings at 25 frames per second, generating 
three replicate histograms that were averaged.
Cryo‑TEM
Ten microliters of uEVs diluted in PBS 1× were placed 
on Formvar-Carbon EM grids and frozen in ethane. 
Fig. 1 UEVs isolation workflow. Schematic representation of protocols tested to isolate uEVs. Supernatants obtained from different procedures (SN0 
to SN7) or treatments (SNa and SNb). uEVs pellets obtained from different procedures (P0–P7)
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Samples were analyzed on a Jeol JEM 2011 transmis-
sion electron microscope at an accelerating voltage of 
200 kV.
Immunoblotting
uEVs suspensions were treated with lysis buffer 1:1 (Tris–
HCl 50 mM pH 7.5, EDTA 1 mM pH 8, NaCl 150 mM, 
SDS 0.1%, NP-40 1%, sodium deoxycholate 0.5%, PIC, 
1:200, NaF 1 mM,  Na3VO4 1 mM). After 1 h shaking at 
4  °C, samples were sonicated at maximum amplitude 
for 5 cycles of 5  s and then centrifuged at 13,000×g for 
15  min at 4  °C. Supernatants were collected and stored 
at − 20 °C. An equal amount of total uEVs lysates (20 µL) 
were mixed with Laemmli sample buffer 1:1 (Tris–HCl 
pH 6.8 0.3 M, SDS 10%, glycerol 5%, β-mercaptoethanol 
2%, bromophenol blue 0.01%) and loaded onto 15% 
acrylamide gel and ran at 100–150  V for 1  h. Proteins 
were transferred to a PVDF 0.2  µm membrane (Immo-
bilon-PSQ) (#ISEQ00010 Millipore, Darmstadt, DE) 
at 100  V for 1  h. Membranes were blocked using 5% 
non-fat dry milk diluted in PBS-T (PBS 1×, Tween-20 
0.1%) and tested against specific primary antibodies: 
TSG101 (#Ab83 Abcam, Cambridge, UK) 1:500 and Alix 
(#Ab76608 Abcam, Cambridge, UK) 1:500. Secondary 
antibodies were rabbit anti-mouse polyclonal and goat 
anti-rabbit polyclonal, respectively (#P0260, #P0448 
Dako, California, EUA) 1:5000. All the antibodies were 
diluted in blocking solution.
Immunoblots were visualized using chemilumines-
cence reagent (#WBLUF0500 Millipore, Darmstadt, DE) 
and Odyssey Fc Imaging System (Li-Cor, Lincoln, NE).
RNA extraction and miRNA expression pattern
uEVs RNA extraction and quantification
For total RNA extraction, 5 different methods were 
tested: miRNeasy Mini kit (#217004 Qiagen), miRCURY 
RNA Isolation kit (#300110 Exiqon, Vedbaek, DK), All-
prep DNA/RNA/miRNA Universal kit (#80224 Qiagen), 
TRIzol LS (#10296010 Life Technologies) and TRIzol 
(#15596026 Life Technologies). Each RNA extraction was 
performed from 100 µL of FHHNC patient’s uEVs. Puri-
fied RNAs were eluted in RNAse-free water and stored at 
− 80 °C. RNA concentrations were measured by capillary 
electrophoresis (Agilent 2100 Bioanalyzer-Picochip).
miRNA profiling
Four nanograms of total RNAs were retrotranscribed 
according to Universal cDNA Synthesis Kit (#203301 
Exiqon, Vedbaek, DK) protocol. cDNAs were diluted at 
1:40 and combined with SYBR Green master mix fol-
lowing the miRCURY LNA Universal microRNA PCR 
(#203403 Exiqon, Vedbaek, DK) instructions. qPCR was 
performed in an ABI7500 Real-Time cycler (Applied 
Biosystems). Primers used were designed to detect: miR-
200c-3p, miR-103a-3p, miR-let7b-5p, miR-99a-5p and 
miR-10b-5p. Unisp6 was added as an exogenous control, 
since they have been found in uEVs [27].
Results
Optimization of urinary exosome‑like vesicles isolation 
protocol
Because of the lack of methodological consensus and the 
imperative need to standardize the uEVs isolation pro-
tocol, we tested several paths based on differential cen-
trifugation steps and sample treatments to determine 
the procedure that provides the purest and highest uEVs 
yield (Fig.  1). Morphology, size and quantity of isolated 
uEVs from a control urine sample pool were evaluated by 
cryo-TEM and NTA.
We first aimed to observe which temperature and time 
of the DTT treatments tested improved the yield and 
purity of uEVs. As shown in Fig. 1, the former 17,000×g 
pellet (P0) was treated with DTT either at 95 °C for 2 min 
or at 37  °C for 10  min and centrifuged at 17,000×g for 
20  min. The uEVs-containing supernatants (SNa and 
SNb) were then ultracentrifuged at 100,000×g for 2  h, 
giving as a result pellets P2 and P3. Cryo-TEM images 
clearly demonstrated that P3 was superior on purity 
when compared with P2, indicating that DTT treatment 
for 10  min at 37  °C (P3) was more efficient depolymer-
izing the THP network than 2  min at 95  °C (P2) treat-
ment (Fig. 2a above). By using NTA we quantified more 
uEVs in P2 than in P3 (Fig. 2b) likely due to the presence 
of impurities (THP complexes) contained in P2. Western 
blot assays for Alix and TSG101 proteins gave negative 
results for P2 and P3, in accordance with the low yield of 
exosomes released from the THP network (Fig. 2e).
We next analyzed whether recovering THP network 
entrapped uEVs might improve the final uEVs yield. For 
this purpose, we mixed SN0 with SNb (Fig. 1) and pro-
ceed with the ultracentrifugation at 100,000×g for 2  h, 
obtaining P4. Cryo-TEM images showed that P4 contains 
highly purified uEVs (Fig.  2a below) that are in higher 
quantities than those observed in P1 and P3, separately, 
upon NTA quantification (Fig.  2b, c). To validate uEVs 
yield by another method and to verify the presence of 
exosome-enriched proteins in the sample, we performed 
immunoblots against two exosomal associated pro-
teins (Alix and TSG101), showing higher expression of 
these proteins in P4 than in P1 (Fig.  2e). In conclusion, 
we could say that mixing uEVs released from the DTT 
treated pellet with SN0 increases the number of uEVs 
without compromising its purity.
NTA profiles of uEVs obtained from the different iso-
lation procedures revealed that mode size falls within 
the expected size range. NTA quantification confirms 













Fig. 2 uEVs characterization. a Representative cryo‑TEM images of all the uEVs pellets obtained from different isolation procedures. Scale bar 
is 100 nm except in P7 which is 200 nm. b NTA results of the uEVs recovered after DTT treatment. P2 showed higher peaks than P3 that might 
correspond to impurities observed by cryo‑TEM. c NTA profiles of the uEVs pellets obtained from the five different uEVs isolation protocols. In all 
cases, the mode size falls within the expected size range. Even though the highest peak is observed in P5, the associated cryo‑TEM image suggests 
that the peak might correspond to impurities. d Bar graph showing uEVs concentration by NTA. Because of P5 impurities, NTA quantification may 
not be accurate. P4 and P6 contained the highest amount of uEVs. Data is expressed as the mean ± SD. e Equal volumes of uEVs (20 µL) were 
loaded for immunoblotting against Alix and TSG101. The strongest signal was obtained in P4, followed by P6. Even though a strong band of Alix 
is observed in P5, this is slightly above the expected weight. f Immunoblotting of uEVs isolated from 300 mL of FHHNC urine, using procedure P4, 
showed a strong intensity of bands corresponding to Alix and TSG101, indicating uEVs presence and its absence in the supernatant
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that P5, obtained after one ultracentrifugation of filtered 
SN0 at 100,000×g for 2 h, exhibits the highest yield, fol-
lowed by P4 (described above), P6 (SN0 at 100,000×g for 
2  h twice), P1 (SN0 at 100,000×g for 2  h once) and P7 
(SN0 at 200,000×g for 1 h once) (Fig. 2c, d). These results 
are in accordance with the visual inspection of uEVs by 
cryo-TEM, except for P5 which seemed to drag some 
unknown material by the filtering process (Fig. 2a below). 
Western blot assays did also agree with previous NTA 
quantification (Fig.  2e). Supernatants SN1, SN3, SN5 
and SN7, resulting from uEVs precipitation steps, were 
included as controls to demonstrate that no exosome 
particles remain in those supernatants.
Overall, data obtained in this study indicate that: (i) the 
protocol used in P5 produces the best yield but the cryo-
TEM images show impurities in the sample that makes it 
unacceptable for further differential expression analyses 
of miRNAs; (ii) the protocol used in P7 is not producing 
enough exosomes for our purposes; (iii) the procedure 
used in P4 is the one that shows the best yield and purity 
followed by the one used in P6. In conclusion, ultracen-
trifugation at 100,000×g for 2 h of mixed SN0 and SNb 
was selected as the preferred protocol for uEVs isolation 
and was the one validated and used in patient’s urine 
samples.
In order to validate the proposed methodology in 
FHHNC patients, whose urine is estimated to be diluted 
at least three times in relation to control urine, we per-
formed the P4 procedure in 300 mL of patients’ urine and 
observed that the selected protocol is suitable for suc-
cessful uEVs isolation from diluted urines (Fig. 2f ).
Evaluation of different RNA extraction methods and miRNA 
expression pattern
A systematic comparison of five different commercial 
RNA extraction methods (mentioned above) was per-
formed with uEVs isolated from a FHHNC patient. Total 
RNA, including miRNAs, were extracted from 100 µL of 
uEVs in each procedure, being miRCURY and TRIzol LS 
the most efficient methods, according to the Agilent 2100 
Bioanalyzer-Picochip quantification analyses (Fig.  3a). 
The miRCURY-RNA profile obtained with Bioanalyzer-
Picochip is shown in Fig.  3b. To evaluate if the RNA 
extraction method could affect the miRNA profile of the 
samples, we analyzed five different miRNAs by qRT-PCR 
(miR-103a-3p, miR-200c-3p, miR-let7b, miR-10b-5p and 
miR-99a-5p). Unisp6 was added as an exogenous control. 
Results obtained in Fig.  3c demonstrated that miRNA 
pattern is similar in all samples, and therefore that the 
RNA extraction method does not have any significant 
effect on miRNA profiling. Unisp6 levels were exactly the 
same for each procedure, validating the assay.
Discussion
Urine sample analysis is irreplaceable as a non-invasive 
method for disease diagnosis and follow-up, particularly 
for kidney diseases. However, non-degraded protein and 
RNA may be only found in uEVs. Unlike tissue biopsy, 
an invasive and expensive procedure that allows only a 
partial sampling of an organ, uEVs provide a full repre-
sentation of the entire urinary system and their study is 
attractive in the field of biomarker discovery in kidney 
diseases. RNA and proteins confined into uEVs can be 
used as a reliable and non-invasive source of information 
of renal cellular and molecular related-events.
There are a growing number of commercial kits for 
uEVs isolation but the results often differ from those 
obtained using traditional isolation techniques. In 
Fig. 3 RNA quantification. a Bar graph of total RNA quantified 
from FHHNC uEVs by Bioanalyzer—Picochip using the five different 
extraction methods. MirCURY kit followed by TRIzol LS were the 
most efficient methods. b A representative electropherogram shows 
that uEVs contain small RNA, including microRNAs (10–40 nt). As 
expected, small amounts of rRNA were detected. c miRNA profiling 
by RT‑qPCR of RNA extracted from FHHNC uEVs. miRNA expression 
pattern is consistent independently of the RNA extraction method
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diseases such as FHHNC, coursing with polyuria, the 
starting quantity of urine required to obtain a good yield 
of uEVs might be higher than in healthy individuals and 
the currently available exosome isolation kits are not 
suitable for our purposes. Therefore, for the aim of this 
pilot study, which is in its discovery phase, we propose 
the use of ultracentrifugation techniques, which are the 
gold standard method for uEVs isolation and allow an 
unlimited urine volume input to obtain enough uEVs in 
highly diluted urine samples.
Diverse protocols based on differential centrifugation 
have been described in several reports [27, 28, 35–39]. 
However, there is no a consensus protocol that would 
provide information on the amount of starting urine 
volume, nor a detailed and thorough procedure that 
could give reliable information on uEVs yield and purity. 
Because we want to use these uEVs for further compara-
tive miRNA profiling of patients suffering from FHHNC, 
the aim of this study was to standardize a differential 
centrifugation protocol for uEVs isolation from diluted 
samples. We validated every step of the ultracentrifuga-
tion process by cryo-TEM, NTA and immunoblotting 
assays, to finally establish a protocol that would be suita-
ble for the accomplishment of our goals and also to select 
the best RNA extraction method for further miRNA 
profiling.
The first issue that we faced was sample handling 
standardization and storage. In rare diseases, such as 
FHNNC, the number of patients is very low and they are 
distributed in different places of the geography which 
requires sample transportation before uEVs isolation. 
Urine, which is a complex fluid, should not be frozen 
before removing cells and cellular debris that can be lysed 
releasing their content in an undesired manner. For this 
reason, and although previous studies recommended 
freezing samples at − 80  °C to loss the minimum uri-
nary exosome-associated proteins after urine collection 
[40], we maintained control sample at 4  °C for 24  h, in 
order to mimic the time-lag and temperature of trans-
portation, and proceed to uEVs isolation afterward. Our 
results indicated that this storage procedure maintained 
uEVs structure in perfect conditions for further analysis, 
as demonstrated by cryo-TEM.
Regarding DTT treatment, there are different recom-
mendations in the literature in terms of time and tem-
perature [25–30]. Our results showed that incubation at 
37 °C for 10 min (P3) is the condition that produced the 
purest uEVs, as well as, an acceptable yield (Fig. 2a above 
and Fig. 2b).
Different speed and ultracentrifugation cycles of SN0 
showed that 100,000×g for 2  h (P1) is more efficient 
than 200,000×g for 1  h (P7). Moreover, uEVs yield was 
improved with the addition of uEVs released from THP 
networks (SNb) to SN0 (P4). Another step analyzed was 
the filtering of SN0 through a 0.22 µm filter [19, 41–43]. 
Unexpectedly, cryo-TEM analysis indicated that filtered 
uEVs contained many impurities (Fig.  2a below), likely 
released by the filter or from disrupted uEVs as a conse-
quence of pressure, producing an over-quantification by 
NTA (Fig. 2c, d). The efficiency of ultracentrifugation in 
uEVs isolation was confirmed by immunoblotting since 
neither Alix nor TSG101 were detected in supernatants 
(Fig.  2e). In accordance with our results, we selected 
P4 as the best protocol to process diluted urine from 
FHHNC patients which is, on average, three times more 
diluted than controls, adapting the protocol to 300 mL of 
starting urine instead of 100 mL. The presence of exoso-
mal-enriched markers (Fig. 2f ), indicated that the volume 
sample input was enough to obtain a sufficient yield of 
uEVs.
An accurate quantification of RNA extracted from 
uEVs, which mainly includes miRNA, represents an 
important bottleneck for comparative expression analy-
ses. Since there are no robust endogenous controls for 
data normalization of miRNA from uEVs, quantifica-
tion should be as accurate as possible. Our next concern 
was then to obtain and quantify, in a reliable manner, the 
RNA yield from the FHHNC uEVs. Five RNA extraction 
methods were compared in different aliquots of the same 
uEVs sample.
Quantification of the RNA obtained by each method 
was based on spectrophotometry (Nanodrop ND-1000), 
capillary electrophoresis (Bioanalyzer—Nanochip and 
Picochip) and fluorescence (Ribogreen) (data not shown). 
In our experience, the Bioanalyzer Picochip, with a detec-
tion range from 50 to 5000 pg/µL, was the most precise, 
consistent and robust method for RNA measurement. 
Therefore, it was used as the reference for other RNA 
quantification methods and selected for further uses. We 
observed that Nanodrop and Ribogreen over- and under-
estimated RNA quantifications, respectively, and Bioana-
lyzer Nanochip, with a detection range from 5 to 500 ng/
µL, provided non-consistent results. Subsequent qRT-
PCR, showing similar expression levels of each miRNA 
among all samples demonstrated the accuracy of the 
Bioanalyzer Picochip method. Albeit the similar miRNA 
expression pattern obtained from the five different RNA 
extraction methods (Fig.  3c), we selected miRCURY kit 
since exhibited the highest RNA yield.
This work has provided with a comprehensive pro-
tocol for reliable uEVs isolation, both from healthy 
individuals and polyuric patients suffering from kid-
ney disease. It covers the conditions for sample pre-
processing, uEVs isolation, characterization and 
quantification, as well as, the conditions for RNA isola-
tion and quantification. This protocol shall be useful for 
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differential high-throughput miRNA expression assays 
between healthy individuals and FHHNC patients that 
might eventually result in the identification of novel 
biomarkers of disease progression and/or therapeutic 
targets.
Conclusions
We established the best protocol for uEVs isolation 
in control samples based on ultracentrifugation at 
100,000×g for 2 h of mixed 17,000×g supernatant (SN0) 
and its pellet treated with DTT for 10 min at 37 °C (SNb). 
This selected protocol was also suitable to threefold 
diluted urine from patients coursing with polyuria such 
as FHHNC patients. Moreover we demonstrated that 
miRNA pattern is independent of the RNA extraction 
method being miRCURY kit and TRIzol LS, with which 
we obtained the highest RNA yield.
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